SB 200646A
Alternative Names: SB 200646Latest Information Update: 26 Nov 1999
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Antidepressants; Antimigraines; Anxiolytics
- Mechanism of Action Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Eating disorders; Major depressive disorder; Migraine; Obsessive-compulsive disorders
Most Recent Events
- 26 Nov 1999 Discontinued-Preclinical for Anxiety disorders in United Kingdom (Unknown route)
- 26 Nov 1999 Discontinued-Preclinical for Depression in United Kingdom (Unknown route)
- 26 Nov 1999 Discontinued-Preclinical for Eating disorders in United Kingdom (Unknown route)